SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.78 USD
+0.08 (2.79%)
Updated Jul 31, 2024 12:22 PM ET
After-Market: $2.84 +0.06 (2.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SABS 2.78 +0.08(2.79%)
Will SABS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SABS
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for SABS
SAB Biotherapeutics Announces Key Executive Appointment
SAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics names Lucy To as CFO
SAB Biotherapeutics appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics management to meet with Oppenheimer